Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer’s disease in a tertiary memory clinic

Abstract Background Knowledge on the effect of analytical variability and storage conditions are essential for the successful implementation of plasma pTau217 in prospective settings. Aims To investigate the performance of plasma pTau217, measured in consecutive samples with LUMIPULSE, for detecting...

Full description

Saved in:
Bibliographic Details
Main Authors: Javier Arranz, Rosa Ferrer, Nuole Zhu, Sara Rubio-Guerra, Íñigo Rodríguez-Baz, José Enrique Arriola-Infante, Lucía Maure-Blesa, Jesús Garcia-Castro, Judit Selma-González, María Carmona-Iragui, Isabel Barroeta, Ignacio Illán-Gala, Miguel Santos-Santos, Juan Fortea, Alberto Lleó, Mireia Tondo, Daniel Alcolea
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Alzheimer’s Research & Therapy
Subjects:
Online Access:https://doi.org/10.1186/s13195-025-01779-7
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849334859917426688
author Javier Arranz
Rosa Ferrer
Nuole Zhu
Sara Rubio-Guerra
Íñigo Rodríguez-Baz
José Enrique Arriola-Infante
Lucía Maure-Blesa
Jesús Garcia-Castro
Judit Selma-González
María Carmona-Iragui
Isabel Barroeta
Ignacio Illán-Gala
Miguel Santos-Santos
Juan Fortea
Alberto Lleó
Mireia Tondo
Daniel Alcolea
author_facet Javier Arranz
Rosa Ferrer
Nuole Zhu
Sara Rubio-Guerra
Íñigo Rodríguez-Baz
José Enrique Arriola-Infante
Lucía Maure-Blesa
Jesús Garcia-Castro
Judit Selma-González
María Carmona-Iragui
Isabel Barroeta
Ignacio Illán-Gala
Miguel Santos-Santos
Juan Fortea
Alberto Lleó
Mireia Tondo
Daniel Alcolea
author_sort Javier Arranz
collection DOAJ
description Abstract Background Knowledge on the effect of analytical variability and storage conditions are essential for the successful implementation of plasma pTau217 in prospective settings. Aims To investigate the performance of plasma pTau217, measured in consecutive samples with LUMIPULSE, for detecting Alzheimer’s disease in a prospective memory clinic setting, along with evaluating its pre-analytical and analytical stability. Methods We prospectively measured pTau217 using the LUMIPULSE automated platform in consecutive patient plasma samples collected between May and November 2024 at the Sant Pau Memory Unit (Barcelona). A subset of participants also underwent paired lumbar puncture for CSF AD biomarkers. We compared biomarker concentrations under different short-term storage conditions (4ºC vs -20ºC) and different protocol pipelines, and assessed lot-to-lot variability. In the subset with available CSF biomarkers, logistic regression was used to evaluate the association between plasma pTau217 and the likelihood of a positive (A +) or a negative (A-) CSF amyloid status. Using ROC analysis, in this prospective cohort we evaluated the accuracy of previously established thresholds derived from historical samples. Results We included 280 participants, divided into two groups: those with (n = 109) and without CSF data (n = 171). Among the subset with CSF, 48% were A + , with a plasma pTau217 fold-change of 4.5 × compared to A-. We found no differences in plasma pTau217 concentrations between either short-term storage conditions. The overall coefficients of analytical variation ranged from 1.8% to 3.2%. Plasma pTau217 concentrations were slightly higher in paired samples of the clinical protocol. Following a two-threshold approach, the need of confirmatory tests (grey zones) after measuring plasma pTau217 ranged between 45.9% and 18.3% using our previously reported strict or lenient cutoffs (overall accuracy 96.6% and 92.1%, respectively). Conclusions The robust stability and low lot-to-lot variability of plasma pTau217 measurement in an automated platform result in high diagnostic performance of this biomarker in the prospective evaluation of patients in a memory clinic setting. These findings support its implementation into clinical routine, offering clinicians an accessible biomarker for AD diagnosis.
format Article
id doaj-art-ab366199f4fb43c0a80a024dd3f6de9c
institution Kabale University
issn 1758-9193
language English
publishDate 2025-07-01
publisher BMC
record_format Article
series Alzheimer’s Research & Therapy
spelling doaj-art-ab366199f4fb43c0a80a024dd3f6de9c2025-08-20T03:45:27ZengBMCAlzheimer’s Research & Therapy1758-91932025-07-0117111310.1186/s13195-025-01779-7Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer’s disease in a tertiary memory clinicJavier Arranz0Rosa Ferrer1Nuole Zhu2Sara Rubio-Guerra3Íñigo Rodríguez-Baz4José Enrique Arriola-Infante5Lucía Maure-Blesa6Jesús Garcia-Castro7Judit Selma-González8María Carmona-Iragui9Isabel Barroeta10Ignacio Illán-Gala11Miguel Santos-Santos12Juan Fortea13Alberto Lleó14Mireia Tondo15Daniel Alcolea16Sant Pau Memory Unit, Department of Neurology, IR SANT PAU, Hospital de La Santa Creu I Sant PauServei de Bioquímica, IR SANT PAU, Hospital de La Santa Creu I Sant Pau, Universitat Autònoma de BarcelonaSant Pau Memory Unit, Department of Neurology, IR SANT PAU, Hospital de La Santa Creu I Sant PauSant Pau Memory Unit, Department of Neurology, IR SANT PAU, Hospital de La Santa Creu I Sant PauSant Pau Memory Unit, Department of Neurology, IR SANT PAU, Hospital de La Santa Creu I Sant PauCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED)Sant Pau Memory Unit, Department of Neurology, IR SANT PAU, Hospital de La Santa Creu I Sant PauSant Pau Memory Unit, Department of Neurology, IR SANT PAU, Hospital de La Santa Creu I Sant PauSant Pau Memory Unit, Department of Neurology, IR SANT PAU, Hospital de La Santa Creu I Sant PauSant Pau Memory Unit, Department of Neurology, IR SANT PAU, Hospital de La Santa Creu I Sant PauSant Pau Memory Unit, Department of Neurology, IR SANT PAU, Hospital de La Santa Creu I Sant PauSant Pau Memory Unit, Department of Neurology, IR SANT PAU, Hospital de La Santa Creu I Sant PauSant Pau Memory Unit, Department of Neurology, IR SANT PAU, Hospital de La Santa Creu I Sant PauSant Pau Memory Unit, Department of Neurology, IR SANT PAU, Hospital de La Santa Creu I Sant PauSant Pau Memory Unit, Department of Neurology, IR SANT PAU, Hospital de La Santa Creu I Sant PauServei de Bioquímica, IR SANT PAU, Hospital de La Santa Creu I Sant Pau, Universitat Autònoma de BarcelonaSant Pau Memory Unit, Department of Neurology, IR SANT PAU, Hospital de La Santa Creu I Sant PauAbstract Background Knowledge on the effect of analytical variability and storage conditions are essential for the successful implementation of plasma pTau217 in prospective settings. Aims To investigate the performance of plasma pTau217, measured in consecutive samples with LUMIPULSE, for detecting Alzheimer’s disease in a prospective memory clinic setting, along with evaluating its pre-analytical and analytical stability. Methods We prospectively measured pTau217 using the LUMIPULSE automated platform in consecutive patient plasma samples collected between May and November 2024 at the Sant Pau Memory Unit (Barcelona). A subset of participants also underwent paired lumbar puncture for CSF AD biomarkers. We compared biomarker concentrations under different short-term storage conditions (4ºC vs -20ºC) and different protocol pipelines, and assessed lot-to-lot variability. In the subset with available CSF biomarkers, logistic regression was used to evaluate the association between plasma pTau217 and the likelihood of a positive (A +) or a negative (A-) CSF amyloid status. Using ROC analysis, in this prospective cohort we evaluated the accuracy of previously established thresholds derived from historical samples. Results We included 280 participants, divided into two groups: those with (n = 109) and without CSF data (n = 171). Among the subset with CSF, 48% were A + , with a plasma pTau217 fold-change of 4.5 × compared to A-. We found no differences in plasma pTau217 concentrations between either short-term storage conditions. The overall coefficients of analytical variation ranged from 1.8% to 3.2%. Plasma pTau217 concentrations were slightly higher in paired samples of the clinical protocol. Following a two-threshold approach, the need of confirmatory tests (grey zones) after measuring plasma pTau217 ranged between 45.9% and 18.3% using our previously reported strict or lenient cutoffs (overall accuracy 96.6% and 92.1%, respectively). Conclusions The robust stability and low lot-to-lot variability of plasma pTau217 measurement in an automated platform result in high diagnostic performance of this biomarker in the prospective evaluation of patients in a memory clinic setting. These findings support its implementation into clinical routine, offering clinicians an accessible biomarker for AD diagnosis.https://doi.org/10.1186/s13195-025-01779-7StabilityPlasmaBiomarkersAlzheimerBloodAmyloid
spellingShingle Javier Arranz
Rosa Ferrer
Nuole Zhu
Sara Rubio-Guerra
Íñigo Rodríguez-Baz
José Enrique Arriola-Infante
Lucía Maure-Blesa
Jesús Garcia-Castro
Judit Selma-González
María Carmona-Iragui
Isabel Barroeta
Ignacio Illán-Gala
Miguel Santos-Santos
Juan Fortea
Alberto Lleó
Mireia Tondo
Daniel Alcolea
Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer’s disease in a tertiary memory clinic
Alzheimer’s Research & Therapy
Stability
Plasma
Biomarkers
Alzheimer
Blood
Amyloid
title Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer’s disease in a tertiary memory clinic
title_full Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer’s disease in a tertiary memory clinic
title_fullStr Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer’s disease in a tertiary memory clinic
title_full_unstemmed Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer’s disease in a tertiary memory clinic
title_short Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer’s disease in a tertiary memory clinic
title_sort prospective evaluation of plasma ptau217 stability for the detection of alzheimer s disease in a tertiary memory clinic
topic Stability
Plasma
Biomarkers
Alzheimer
Blood
Amyloid
url https://doi.org/10.1186/s13195-025-01779-7
work_keys_str_mv AT javierarranz prospectiveevaluationofplasmaptau217stabilityforthedetectionofalzheimersdiseaseinatertiarymemoryclinic
AT rosaferrer prospectiveevaluationofplasmaptau217stabilityforthedetectionofalzheimersdiseaseinatertiarymemoryclinic
AT nuolezhu prospectiveevaluationofplasmaptau217stabilityforthedetectionofalzheimersdiseaseinatertiarymemoryclinic
AT sararubioguerra prospectiveevaluationofplasmaptau217stabilityforthedetectionofalzheimersdiseaseinatertiarymemoryclinic
AT inigorodriguezbaz prospectiveevaluationofplasmaptau217stabilityforthedetectionofalzheimersdiseaseinatertiarymemoryclinic
AT joseenriquearriolainfante prospectiveevaluationofplasmaptau217stabilityforthedetectionofalzheimersdiseaseinatertiarymemoryclinic
AT luciamaureblesa prospectiveevaluationofplasmaptau217stabilityforthedetectionofalzheimersdiseaseinatertiarymemoryclinic
AT jesusgarciacastro prospectiveevaluationofplasmaptau217stabilityforthedetectionofalzheimersdiseaseinatertiarymemoryclinic
AT juditselmagonzalez prospectiveevaluationofplasmaptau217stabilityforthedetectionofalzheimersdiseaseinatertiarymemoryclinic
AT mariacarmonairagui prospectiveevaluationofplasmaptau217stabilityforthedetectionofalzheimersdiseaseinatertiarymemoryclinic
AT isabelbarroeta prospectiveevaluationofplasmaptau217stabilityforthedetectionofalzheimersdiseaseinatertiarymemoryclinic
AT ignacioillangala prospectiveevaluationofplasmaptau217stabilityforthedetectionofalzheimersdiseaseinatertiarymemoryclinic
AT miguelsantossantos prospectiveevaluationofplasmaptau217stabilityforthedetectionofalzheimersdiseaseinatertiarymemoryclinic
AT juanfortea prospectiveevaluationofplasmaptau217stabilityforthedetectionofalzheimersdiseaseinatertiarymemoryclinic
AT albertolleo prospectiveevaluationofplasmaptau217stabilityforthedetectionofalzheimersdiseaseinatertiarymemoryclinic
AT mireiatondo prospectiveevaluationofplasmaptau217stabilityforthedetectionofalzheimersdiseaseinatertiarymemoryclinic
AT danielalcolea prospectiveevaluationofplasmaptau217stabilityforthedetectionofalzheimersdiseaseinatertiarymemoryclinic